Delayed Transcapillary Transport of Insulin to Muscle Interstitial Fluid in Obese Subjects

  1. Mikaela Sjöstrand1,
  2. Soffia Gudbjörnsdottir1,
  3. Agneta Holmäng2,
  4. Lars Lönn3,
  5. Lena Strindberg1 and
  6. Peter Lönnroth1
  1. 1Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Göteborg, Sweden
  2. 2Wallenberg Laboratory, Sahlgrenska University Hospital, Göteborg, Sweden
  3. 3Department of Radiology, Sahlgrenska University Hospital, Göteborg, Sweden

    Abstract

    Insulin-resistant subjects have a slow onset of insulin action, and the underlying mechanism has not been determined. To evaluate whether a delayed transcapillary transport is part of the peripheral insulin resistance, we followed the kinetics of infused insulin and inulin in plasma and muscle interstitial fluid in obese insulin-resistant patients and control subjects. A total of 10 lean and 10 obese men (BMI 24 ± 0.8 vs. 32 ± 0.8 kg/m2, P < 0.001) was evaluated during a hyperinsulinemic-euglycemic clamp (insulin infusion rate 120 mU · m−2 · min−1) combined with an inulin infusion. Measurements of insulin and inulin in plasma were taken by means of arterial-venous catheterization of the forearm and microdialysis in brachioradialis muscle combined with forearm blood flow measurements with vein occlusion pletysmography. The obese subjects had a significantly lower steady-state glucose infusion rate and, moreover, demonstrated a delayed appearance of insulin (time to achieve half-maximal concentration [T1/2] 72 ± 6 vs. 46 ± 6 min in control subjects, P < 0.05) as well as inulin (T1/2 83 ± 3 vs. 53 ± 7 min, P < 0.01) in the interstitial fluid. Also, the obese subjects had a delayed onset of insulin action (T1/2 70 ± 9 vs. 45 ± 5 min in control subjects, P < 0.05), and their forearm blood flow rate was significantly lower. These results demonstrate a delayed transcapillary transport of insulin and inulin from plasma to the muscle interstitial fluid and a delayed onset of insulin action in insulin-resistant obese subjects.

    Footnotes

    • Address correspondence and reprint requests to Mikaela Sjö strand, MD, Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden. E-mail: mikaela.sjostrand{at}medic.gu.se.

      Received for publication 13 February 2002 and accepted in revised form 23 May 2002.

      A-V, arterial-venous; CT, computed tomography; GIR, glucose infusion rate; HGP, hepatic glucose production; PS, permeability surface area product; T1/2, time to achieve half-maximal concentration; Tmax, time to achieve maximal concentration.

    « Previous | Next Article »Table of Contents